US · antibody-drug conjugates · biotech · cancer
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series B · Apr 2026 · $137M
Novartis Venture Fund lead, Frazier Life Sciences lead, DCVC Bio, Alexandria Venture Investments, OrbiMed, Longwood Fund, Astellas Venture Management, Goldman Sachs Alternatives’ Life Sciences team, Samsara BioCapital
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.